Table 3.
Univariable and multivariable logistic regression analyses of factors associated with long-term survivors (≥ 5 years).
| Univariable | Multivariable | |||
|---|---|---|---|---|
| Odds ratio (95% CI) | p value | Odds ratio (95% CI) | p value | |
| All patients (N = 38,708) | ||||
| Age (years) | 0.977 (0.972–0.981) | < 0.001 | 0.984 (0.979–0.989) | < 0.001 |
| Female gender | 1.16 (1.05–1.29) | 0.005 | 1.13 (1.01–1.27) | 0.031 |
| Tumour location | ||||
| Head | 1 (reference) | |||
| Body | 0.434 (0.354–0.532) | < 0.001 | ||
| Tail | 0.590 (0.494–0.703) | < 0.001 | ||
| Other | 0.412 (0.353–0.480) | < 0.001 | ||
| Grade | ||||
| Well differentiated | 1 (reference) | 1 (reference) | ||
| Moderately differentiated | 0.657 (0.561–0.770) | < 0.001 | 0.557 (0.464–0.667) | < 0.001 |
| Poorly differentiated/anaplastic | 0.319 (0.271–0.376) | < 0.001 | 0.382 (0.318–0.459) | < 0.001 |
| Tumour size (cm) | 0.637 (0.609–0.666) | < 0.001 | 0.878 (0.837–0.920) | < 0.001 |
| T stage | ||||
| T1 | 1 (reference) | 1 (reference) | ||
| T2 | 0.210 (0.172–0.257) | < 0.001 | 0.560 (0.431–0.726) | < 0.001 |
| T3 | 0.282 (0.238–0.336) | < 0.001 | 0.347 (0.275–0.438) | < 0.001 |
| T4 | 0.061 (0.047–0.079) | < 0.001 | 0.247 (0.177–0.344) | < 0.001 |
| N stage | 0.972 (0.872–1.08) | 0.613 | ||
| M stage | 0.075 (0.062–0.091) | < 0.001 | 0.320 (0.256–0.400) | < 0.001 |
| Surgical resection | 23.2 (20.2–26.6) | < 0.001 | 10.8 (9.13–12.8) | < 0.001 |
| Chemotherapy | 2.04 (1.82–2.29) | < 0.001 | 1.45 (1.27–1.64) | < 0.001 |
| Radiation | 3.06 (2.74–3.40) | < 0.001 | ||
| Surgically resected patients (N = 7564) | ||||
| Age (years) | 0.988 (0.983–0.994) | < 0.001 | 0.988 (0.982–0.994) | < 0.001 |
| Female gender | 1.19 (1.05–1.34) | 0.007 | 1.18 (1.03–1.34) | 0.014 |
| Tumour location | ||||
| Head | 1 (reference) | |||
| Body | 1.33 (1.04–1.70) | 0.025 | ||
| Tail | 1.26 (1.02–1.55) | 0.030 | ||
| Other | 0.969 (0.791–1.19) | 0.762 | ||
| Grade | ||||
| Well differentiated | 1 (reference) | 1 (reference) | ||
| Moderately differentiated | 0.520 (0.425–0.635) | < 0.001 | 0.590 (0.474–0.734) | < 0.001 |
| Poorly differentiated/anaplastic | 0.333 (0.270–0.411) | < 0.001 | 0.431 (0.343–0.542) | < 0.001 |
| Tumour size (cm) | 0.753 (0.715–0.792) | < 0.001 | 0.857 (0.813–0.904) | < 0.001 |
| T stage | ||||
| T1 | 1 (reference) | 1 (reference) | ||
| T2 | 0.439 (0.343–0.561) | < 0.001 | 0.680 (0.515–0.897) | 0.006 |
| T3 | 0.252 (0.205–0.311) | < 0.001 | 0.467 (0.367–0.594) | < 0.001 |
| T4 | 0.092 (0.059–0.141) | < 0.001 | 0.176 (0.111–0.280) | < 0.001 |
| N stage | 0.348 (0.306–0.396) | < 0.001 | 0.384 (0.335–0.440) | < 0.001 |
| M stage | 0.189 (0.121–0.295) | < 0.001 | 0.236 (0.149–0.371) | < 0.001 |
| Chemotherapy | 1.46 (1.27–1.67) | < 0.001 | 1.68 (1.44–1.95) | < 0.001 |
| Radiation | 1.40 (1.23–1.58) | < 0.001 | ||
| Non-resected patients (N = 30,772) | ||||
| Age (years) | 0.975 (0.965–0.985) | < 0.001 | 0.967 (0.957–0.977) | < 0.001 |
| Female gender | 1.02 (0.795–1.31) | 0.881 | ||
| Tumour location | ||||
| Head | 1 (reference) | |||
| Body | 0.446 (0.273–0.729) | 0.001 | ||
| Tail | 0.475 (0.294–0.768) | 0.002 | ||
| Other | 0.895 (0.673–1.19) | 0.444 | ||
| Grade | ||||
| Well differentiated | 1 (reference) | 1 (reference) | ||
| Moderately differentiated | 0.491 (0.342–0.704) | < 0.001 | 0.540 (0.376–0.776) | 0.001 |
| Poorly differentiated/anaplastic | 0.272 (0.181–0.409) | < 0.001 | 0.332 (0.220–0.499) | < 0.001 |
| Tumour size (cm) | 0.889 (0.814–0.970) | 0.009 | ||
| T stage | ||||
| T1 | 1 (reference) | 1 (reference) | ||
| T2 | 0.395 (0.210–0.744) | 0.004 | 0.416 (0.217–0.797) | 0.009 |
| T3 | 0.350 (0.188–0.653) | 0.001 | 0.311 (0.164–0.591) | 0.001 |
| T4 | 0.382 (0.206–0.710) | 0.003 | 0.300 (0.157–0.573) | < 0.001 |
| N stage | 0.665 (0.490–0.902) | 0.009 | 0.701 (0.512–0.960) | 0.027 |
| M stage | 0.371 (0.283–0.486) | < 0.001 | 0.358 (0.269–0.477) | < 0.001 |
| Chemotherapy | 1.52 (1.18–1.97) | 0.001 | ||
| Radiation | 1.82 (1.36–2.43) | < 0.001 | ||
N, number of non-missing values.